The drug candidate rocatinlimab for the therapy of atopic eczema met its main and secondary endpoints in a part III trial.
发布者：BY MARIA OUTZE NIELSEN，转转请注明出处：https://robotalks.cn/amgen-achieves-positive-results-with-candidate-for-atopic-eczema/
Amgen achieves positive results with candidate for atopic eczema
赞 (0)
关于作者
Novo Nordisk EVP pleased with new obesity data despite price drop
上一篇
11 3 月, 2025 12:17 下午
Roche hires Novo executive to help push into obesity drug market
下一篇
11 3 月, 2025 12:18 下午
相关推荐
-
Dept. of Energy Announces $40M in Funds to Boost Solar Energy Supply Chain
Around $16 numerous those funds be split throughout 4 solar innovation r & d jobs.
-
NASCAR Unveils Electric Race Car Prototype
NASCAR, the supply vehicle auto racing approving body recognized for its high-octane occasions throughout the USA, is taking a considerable action towards a greener future. In July…
-
Why it’s important to read aloud to your kids—even after they can read themselves
Reads to your children a going to bed routine in your house? For a lot of us, it will certainly be a natural memory of our very own youths. Or of the moment increasing currently fu…
-
Procurement Training Budgets Are Low—Can AI Fill the Gap?
Purchase encounters an expanding abilities void as AI fostering increases, however several business aren’t budgeting for training.
